FDA Approves Bimekizumab for Adults with Plaque Psoriasis; The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.

Media coverage

• Title	FDA Approves Bimekizumab for Adults with Plaque Psoriasis; The approval for the IL-17A and IL-17F inhibitor is supported by data showing about 80% of patients achieved nearly clear skin within 4 doses.
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	18/10/23
  Persons	Mark Lebwohl

• Title	FDA Approves Bimekizumab for Adults with Plaque Psoriasis
  Media name/outlet	HCP Live
  Country/Territory	United States
  Date	18/10/23
  Persons	Mark Lebwohl